DCS Advisory Acts as Exclusive Financial Advisor to Chiral Technologies, Inc. on its Acquisition of Arbor Biosciences
Daicel is a global market leader in enantioselective chromatography. With the acquisition of Arbor Biosciences, Chiral and Daicel will gain business platforms in the genomics field and aim to provide broader solutions in the food, environment, and medical health care fields.
“As we diversify our product portfolio to serve the needs of biopharma, Arbor Biosciences delivers the molecular biology foundation to fuel that growth,” stated Joseph Barendt, Ph.D., President of Chiral Technologies, Inc.
“When beginning the search for the right target to grow our business and increase our expertise in this critical and complex area, we knew we needed advisors who understood the complexities of our space as well as we did. The team at DCS Advisory provided us with excellent guidance throughout and orchestrated a seamless, efficient process,” Dr. Barendt continued.
About DCS Advisory
DCS Advisory LLC is a leading investment bank specializing in M&A and private capital raising. DCS Advisory is a wholly owned subsidiary of Daiwa Capital Markets America Holdings Inc. and is an indirect subsidiary of Daiwa Securities Group Inc. Along with sister company DC Advisory, other Daiwa affiliates, and alliance partners, DCS Advisory is part of an established global brand with more than 900 professionals in 34 offices throughout the Americas, Europe and Asia. DCS Advisory covers a broad range of industries including Aerospace, Defense and Government Services, Business and Tech-Enabled Services, Industrials, Consumer, Retail and Leisure, Media and Telecom, and Technology and Software. For more information please visit www.dcsadvisory.com.
These materials have been prepared by DCS Advisory solely for informational purposes and do not constitute or form part of, and should not be construed as, an offer to sell or issue, a solicitation of an offer to buy, or a recommendation with respect to any securities.